Harrow Health Inc
Change company Symbol lookup
Select an option...
HROW Harrow Health Inc
UPC Universe Pharmaceuticals Inc
MHH Mastech Digital Inc
GCTK GlucoTrack Inc
KODK Eastman Kodak Co
FYBR Frontier Communications Parent Inc
TPNEF Cub Energy Inc
ECC Eagle Point Credit Co LLC
CPHI China Pharma Holdings Inc
SHOP Shopify Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Harrow Health, Inc. is an ophthalmic-focused healthcare company. The Company's business specializes in the development, production and sale of medications that serve unmet needs in the marketplace through its subsidiaries and deconsolidated companies. The Company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical business, and Visionology, Inc. (Visionology), a direct-to-consumer eye care subsidiary focused on chronic eye disease. In addition, the Company holds non-controlling equity positions in Surface Ophthalmics, Inc. (Surface) and Melt Pharmaceuticals, Inc. (Melt). It also owns royalty rights in various drug candidates being developed by Surface and Melt.

Closing Price
$8.44
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
66,952
0

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Target Corporation - TGT

2:45 pm ET June 29, 2022 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / June 29, 2022 / Pomerantz LLP is investigating claims on behalf of investors of Target Corporation("Target" or the "Company") (NYSE:TGT). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.comor 888-476-6529, ext. 7980.

The investigation concerns whether Target and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On May 18, 2022, Target announced its first quarter 2022 financial results in a press release. The Company also provided guidance, expecting second quarter 2022 "operating income margin rate [to] be in a wide range centered around first quarter's operating margin rate of 5.3 percent." Just three weeks later, on June 7, 2022, Target revised its guidance, expecting the second quarter 2022 operating margin rate to "be in a range around 2%." The Company attributed the change to "a set of actions to right-size [Target's] inventory for the balance of the year[.]"

On this news, Target's stock price fell $3.69 per share, or 2.31%, to close at $155.98 per share on June 7, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com

SOURCE: Pomerantz LLP





View source version on accesswire.com:

https://www.accesswire.com/707061/SHAREHOLDER-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-Target-Corporation--TGT



comtex tracking

COMTEX_409434400/2457/2022-06-29T14:45:54

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.